[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive...

APGE : 134.55 (-0.10%)
Apogee Therapeutics: AbbVie's Billion-Dollar Bet Might Have Papered Over the Clinical Cracks

Barchart Research What to Expect from APGE Earnings APGE Generated August 7, 2026 Current Price $134.84 EPS Estimate $$-1.10 Consensus Rating Hold Average Move 4.24% Apogee Therapeutics: AbbVie's Billion-Dollar...

APGE : 134.55 (-0.10%)
Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

APGE : 134.55 (-0.10%)
SLP : 18.32 (+0.05%)
DSGR : 34.81 (-0.17%)
AVB : 180.80 (+0.56%)
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics...

APGE : 134.55 (-0.10%)
ABBV : 251.16 (+0.97%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRBG, RMAX, GBCS, and APGE

NEW YORK , July 14, 2026 /PRNewswire/ --

APGE : 134.55 (-0.10%)
RMAX : 12.30 (-0.24%)
GBCS : 5.6000 (-0.88%)
CRBG : 33.78 (+1.17%)
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

APGE : 134.55 (-0.10%)
LLY : 1,226.44 (+0.50%)
ABBV : 251.16 (+0.97%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--AVB, APGE, TMHC, and LPRO

NEW YORK , July 6, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

LPRO : 3.14 (-0.32%)
APGE : 134.55 (-0.10%)
TMHC : 72.45 (-0.03%)
AVB : 180.80 (+0.56%)
Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

APGE : 134.55 (-0.10%)
CBAN : 22.01 (-0.23%)
INVE : 2.65 (+1.07%)
FSRL : 19.9800 (+0.35%)
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS

NEW YORK , July 2, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

APGE : 134.55 (-0.10%)
BOLD : 2.78 (+1.09%)
GBCS : 5.6000 (-0.88%)
ACA : 145.05 (+0.10%)
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

REFI : 10.35 (-1.00%)
TECH : 72.26 (+0.04%)
APGE : 134.55 (-0.10%)
BOLD : 2.78 (+1.09%)

Barchart Exclusives

Why Wall Street Isn't Buying Super Micro's $60 Billion Backlog Quite Yet
While the record backlog and strong demand are likely to translate into sustainable revenue growth, Wall Street analysts aren't bullish on SMCI stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.